Glioblastoma Multiforme (GBM) Treatment Market Report 2026

The glioblastoma multiforme (gbm) treatment market size has grown rapidly in recent years. It will grow from $2.73 billion in 2025 to $3.02 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to limited survival outcomes, reliance on surgery and radiation, chemotherapy standardization, growth of neuro-oncology centers, increased brain tumor diagnosis.

The glioblastoma multiforme (gbm) treatment market size is expected to see rapid growth in the next few years. It will grow to $4.46 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to development of targeted therapies, expansion of immunotherapy pipelines, precision medicine adoption, increased clinical trial activity, rising research funding. Major trends in the forecast period include rising adoption of multimodal treatment regimens, increased use of tumor treating field therapy, growing focus on personalized gbm therapies, expansion of immunotherapy approaches, improved post-surgical treatment protocols.

The rising prevalence of brain disorders is expected to drive the growth of the glioblastoma multiforme (GBM) treatment market in the coming years. Brain disorders are conditions that impair the normal functioning of the brain, nerves throughout the body, and the spinal cord. The increasing occurrence of brain disorders, including glioblastoma multiforme (GBM), is influenced by factors such as aging populations, weakened immune systems, overdiagnosis, exposure to ionizing radiation, air pollution, and other environmental and lifestyle factors, creating a greater need for effective treatments to improve patient well-being. For instance, in February 2025, Dementia Australia, a non-profit organization, reported that around 433,300 Australians were living with dementia, with projections reaching 812,500 by 2054. Additionally, younger-onset dementia affected approximately 29,000 people in 2025, expected to rise to 41,000 by 2054. Therefore, the growing prevalence of brain disorders is driving the glioblastoma multiforme (GBM) treatment market.

Key companies in the market are focusing on the development of innovative wearable and portable devices to strengthen their market presence. These advancements aim to provide enhanced functionality, convenience, and comfort, addressing the increasing demand for accessible and efficient healthcare solutions. For example, in 2023, Novocure, a Jersey-based oncology company, launched Optune Gio, a wearable and portable treatment system for newly diagnosed glioblastoma (GBM) patients, approved by the FDA. This device utilizes Tumor Treating Fields (TTFields), which are alternating electric fields that interfere with cancer cell division, potentially extending patient survival. Weighing just 2.7 pounds, Optune Gio is designed for comfort, allowing patients to continue daily activities while undergoing treatment.

In October 2024, Merck & Co., a US-based pharmaceutical company specializing in prescription medicines and vaccines, acquired Modifi Biosciences for an undisclosed amount. This acquisition allows Merck to enhance its oncology pipeline by incorporating Modifi’s preclinical small-molecule platform, which targets cancer cells with DNA repair defects, including those lacking the O6-methylguanine-DNA methyltransferase (MGMT) protein, and shows potential against highly refractory tumors such as glioblastoma. Modifi Biosciences Inc. is a US-based company focused on developing treatments for glioblastoma multiforme (GBM).

Major companies operating in the glioblastoma multiforme (gbm) treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, AstraZeneca PLC, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Jazz Pharmaceuticals Inc., Sumitomo Dainippon Pharma Oncology Inc., Varian Medical Systems Inc., Amneal Pharmaceuticals Inc., Elekta AB, Loxo Oncology Inc., Karyopharm Therapeutics Inc., EnGeneIC Ltd., Genenta Science S.r.l., Cantex Pharmaceuticals Inc., Vascular Biogenics Ltd., Seelos Therapeutics Inc, Angiochem Inc., Diffusion Pharmaceuticals Inc.

North America was the largest region in the glioblastoma multiforme (GBM) treatment market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme (gbm) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glioblastoma multiforme (gbm) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the glioblastoma multiforme (gbm) treatment market by increasing costs of imported oncology drugs, treatment devices, and diagnostic imaging systems. Hospitals and cancer treatment centers are most affected due to dependence on imported therapies. These tariffs raise treatment costs but support domestic production of oncology drugs and medical devices.

The glioblastoma multiforme (gbm) treatment market research report is one of a series of new reports that provides glioblastoma multiforme (gbm) treatment market statistics, including glioblastoma multiforme (gbm) treatment industry global market size, regional shares, competitors with a glioblastoma multiforme (gbm) treatment market share, detailed glioblastoma multiforme (gbm) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the glioblastoma multiforme (gbm) treatment industry. This glioblastoma multiforme (gbm) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glioblastoma multiforme (GBM) treatment involves the management and care of patients with glioblastoma multiforme, a rapidly growing tumor of the brain or spinal cord. This primary malignant brain tumor is most prevalent in adults.

The main treatment options for glioblastoma multiforme (GBM) include surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating field (TTF) therapy, and immunotherapy. Surgery is a medical approach that uses manual and instrumental techniques to treat wounds, diseases, and other health conditions. The drug types used in treatment include temozolomide, bevacizumab, lomustine, carmustine wafers, and others. These medications are administered orally, parenterally, and through other routes, and are utilized by hospitals, clinics, and ambulatory surgical centers.

The glioblastoma multiforme (GBM) treatment market includes revenues earned by entities by performing neurological exams, imaging tests, surgical operations, radiotherapy, and molecular profiling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.